30 results on '"Roselli, J."'
Search Results
2. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study
- Author
-
Saibeni, S., primary, Bezzio, C., additional, Bossa, F., additional, Privitera, A.C., additional, Marchi, S., additional, Roselli, J., additional, Mazzuoli, S., additional, Geccherle, A., additional, Soriano, A., additional, Principi, M.B., additional, Viola, A., additional, Sarpi, L., additional, Cappello, M., additional, D'Incà, R., additional, Mastronardi, M., additional, Bodini, G., additional, Guerra, M., additional, Benedetti, A., additional, Romano, M., additional, Cicala, M., additional, Sabatino, A. Di, additional, Scaldaferri, F., additional, De Rosa, T., additional, Giardino, A.M., additional, Germano, V., additional, Orlando, A., additional, and Armuzzi, A., additional
- Published
- 2023
- Full Text
- View/download PDF
3. P150 Increased risk of ibd flare after sars-cov-2 infection. who’s the more guilty: viral infection or therapy withdrawal?
- Author
-
Bezzio, C, primary, Guarino, A D, additional, Fiorino, G, additional, Armuzzi, A, additional, Ribaldone, D G, additional, Furfaro, F, additional, Pugliese, D, additional, Vernero, M, additional, Variola, A, additional, Gerardi, V, additional, Scucchi, L, additional, Viganò, C, additional, Caprioli, F A, additional, Roselli, J, additional, Coppini, F, additional, Ardizzone, S, additional, Onali, S, additional, Zingone, F, additional, Daperno, M, additional, Cortellezzi, C, additional, Carparelli, S, additional, Soriano, A, additional, Manes, G, additional, and Saibeni, S, additional
- Published
- 2022
- Full Text
- View/download PDF
4. AF.45 IBUS-SAS FOR CROHN’S DISEASE ULTRASOUND ACTIVITY: INITIAL VALIDATION AND RESEARCH OF THE OPTIMAL CUT-OFF SCORE
- Author
-
Dragoni, G., primary, Innocenti, T., additional, Lynch, E.N., additional, Fiorini, C., additional, Parisio, L., additional, Roselli, J., additional, Bagnoli, S., additional, Macrì, G., additional, Rogai, F., additional, Milani, S., additional, Galli, A., additional, and Milla, M., additional
- Published
- 2021
- Full Text
- View/download PDF
5. AF.59 PREGNANCY AND INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE ANALYSIS OF A LARGE COHORT FROM A TERTIARY REFERRAL CENTRE
- Author
-
Roselli, J., primary, Taylor, A., additional, Innocenti, T., additional, Dragoni, G., additional, Gottin, M., additional, Lynch, E.N., additional, Campani, C., additional, Bagnoli, S., additional, Macrì, G., additional, Rogai, F., additional, Milani, S., additional, Galli, A., additional, and Milla, M., additional
- Published
- 2021
- Full Text
- View/download PDF
6. P141 IBUS-SAS for Crohn’s disease ultrasound activity: initial validation and research of the optimal cut-off score
- Author
-
Dragoni, G, primary, Innocenti, T, additional, Lynch, E N, additional, Fiorini, C, additional, Parisio, L, additional, Roselli, J, additional, Bagnoli, S, additional, Macrì, G, additional, Rogai, F, additional, Milani, S, additional, Galli, A, additional, and Milla, M, additional
- Published
- 2021
- Full Text
- View/download PDF
7. P491 Infectious risk of vedolizumab compared with other biological agents in the treatment of Inflammatory Bowel Disease
- Author
-
Innocenti, T, primary, Roselli, J, additional, Lynch, E N, additional, Apolito, P, additional, Parisio, L, additional, Bagnoli, S, additional, Macrì, G, additional, Rogai, F, additional, Milani, S, additional, Galli, A, additional, Milla, M, additional, and Dragoni, G, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV 2 infection: an IG-IBD study
- Author
-
Bezzio, C., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Carparelli, S., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Fiorino, G., Saibeni, S., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Pugliese, D., Allocca, M., Ferretti, F., Roselli, J., Bossa, F., Giuliano, A., Piazza, N., Manes, G., Sartini, A., Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Casini, V., Soriano, A., Amato, A., Grossi, L., Onali, S., Rottoli, M., Spagnuolo, R., Baroni, S., Cortelezzi, C. C., Baldoni, M., Vernero, M., Scaldaferri, F., Maconi, G., Guarino, A. D., Palermo, A., D'Inca, R., Scribano, M. L., Biancone, L., Carrozza, L., Ascolani, M., Costa, F., Di Sabatino, A., Zammarchi, I., Gottin, M., Conforti, F. S., Bezzio, Cristina, Armuzzi, Alessandro, Furfaro, Federica, Ardizzone, Sandro, Milla, Monica, Carparelli, Sonia, Orlando, Ambrogio, Caprioli, Flavio Andrea, Castiglione, Fabiana, Viganò, Chiara, Ribaldone, Davide Giuseppe, Zingone, Fabiana, Monterubbianesi, Rita, Imperatore, Nicola, Festa, Stefano, Daperno, Marco, Scucchi, Ludovica, Ferronato, Antonio, Pastorelli, Luca, Balestrieri, Paola, Ricci, Chiara, Cappello, Maria, Felice, Carla, Fiorino, Gionata, Saibeni, Simone, and Francesca Coppini, Patrizia Alvisi, Viviana Gerardi, Angela Variola, Silvia Mazzuoli, Marco Vincenzo Lenti, Daniela Pugliese, Mariangela Allocca, Francesca Ferretti, Jenny Roselli, Fabrizio Bossa, Alessandra Giuliano, Nicole Piazza, Gianpiero Manes, Alessandro Sartini, Andrea Buda, Federica Micheli, Valeria Ciardo, Giovanni Casella, Angelo Viscido, Giorgia Bodini, Valentina Casini, Alessandra Soriano, Arnaldo Amato, Laurino Grossi, Sara Onali, Matteo Rottoli, Rocco Spagnuolo, Stefania Baroni, Claudio Cortelezzi, Monia Baldoni, Marta Vernero, Franco Scaldaferri, Giovanni Maconi, Alessia Dalila Guarino, Andrea Palermo, Renata D'Incà, Maria Lia Scribano, Livia Biancone, Lucio Carrozza, Marta Ascolani, Francesco Costa, Antonio Di Sabatino, Irene Zammarchi, Matteo Gottin, Francesco Simone Conforti
- Subjects
medicine.medical_specialty ,Settore MED/12 - GASTROENTEROLOGIA ,IBD ,Population ,Ulcerative ,Disease ,Lower risk ,Asymptomatic ,Inflammatory bowel disease ,Aged ,Humans ,SARS-CoV-2 ,Tumor Necrosis Factor Inhibitors ,COVID-19 ,Colitis, Ulcerative ,Crohn Disease ,Inflammatory Bowel Diseases ,IBD Treatments and Sars‐cov‐2 Infection ,Internal medicine ,medicine ,biologics ,Pharmacology (medical) ,education ,therapy ,education.field_of_study ,Hepatology ,business.industry ,INFLAMMATORY BOWEL DISEASE ,Gastroenterology ,medicine.disease ,Colitis ,Ulcerative colitis ,Pneumonia ,Original Article ,medicine.symptom ,business ,Cohort study - Abstract
Summary Background Older age and comorbidities are the main risk factors for adverse COVID‐19 outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications is still under investigation. Aims To assess risk factors for adverse outcomes of COVID‐19 in IBD patients and use the identified risk factors to build risk indices. Methods Observational cohort study. Univariable and multivariable logistic regression was used to identify risk factors associated with pneumonia, hospitalisation, need for ventilatory support, and death. Results Of the 937 patients (446 with ulcerative colitis [UC]) evaluated, 128 (13.7%) had asymptomatic SARS‐CoV‐2 infection, 664 (70.8%) had a favourable course, and 135 (15.5%) had moderate or severe COVID‐19. In UC patients, obesity, active disease and comorbidities were significantly associated with adverse outcomes. In patients with Crohn's disease (CD), age, obesity, comorbidities and an additional immune‐mediated inflammatory disease were identified as risk factors. These risk factors were incorporated into two indices to identify patients with UC or CD with a higher risk of adverse COVID‐19 outcomes. In multivariable analyses, no single IBD medication was associated with poor COVID‐19 outcomes, but anti‐TNF agents were associated with a lower risk of pneumonia in UC, and lower risks of hospitalisation and severe COVID‐19 in CD. Conclusion The course of COVID‐19 in patients with IBD is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID‐19 outcomes. IBD medications do not pose additional risks. The risk indices may help to identify patients who should be prioritised for COVID‐19 re‐vaccination or for therapies for SARS‐CoV‐2 infection., The course of COVID‐19 in patients with IBD patients is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID‐19 outcomes. IBD medications do not pose additional risks.
- Published
- 2021
9. T02.02.6 NON-SMALL-BOWEL LESIONS IDENTIFICATION BY CAPSULE ENDOSCOPY: A SINGLE CENTRE RETROSPECTIVE STUDY
- Author
-
Innocenti, T., primary, Dragoni, G., additional, Roselli, J., additional, Macrì, G., additional, Mello, T., additional, Milani, S., additional, and Galli, A., additional
- Published
- 2020
- Full Text
- View/download PDF
10. T04.01.13 RISK OF INFECTIOUS COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH VEDOLIZUMAB: A REAL LIFE EXPERIENCE
- Author
-
Apolito, P., primary, Innocenti, T., additional, Roselli, J., additional, Parisio, L., additional, Macrì, G., additional, Bagnoli, S., additional, Rogai, F., additional, Galli, A., additional, and Milla, M., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Resistencia a los antihelmínticos en bovinos del nordeste de Corrientes (Argentina)
- Author
-
Lobayan, S. I., primary, Schapiro, J. H., additional, Fiel, C. A., additional, Zabalo, M. M., additional, and Roselli, J. G., additional
- Published
- 2017
- Full Text
- View/download PDF
12. International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams
- Author
-
Augestad KM, Lindsetmo RO, Stulberg J, Reynolds H, Senagore A, Champagne B, Heriot AG, Leblanc F, Delaney CP, Ambrosetti P, Andujar J, Baixuli J, Balen E, Baxter N, Beck D, Bemelman W, Bergamaschi R, Billingham R, Birch D, Bonardi R, Bonardi M, Bonjer J, Braga M, Buch H, Buechler M, Burnstein M, Campbell K, Caushaj P, Celebrezze J, Chang G, Cheong D, Cohen J, Colak T, Delaney C, Dhoore A, Douglas P, Dozois E, Efron J, Ellis N, Enker W, Fanelli RD, Fazio V, Fleshman J, Franklin M, Fry R, Garcia Aguilar J, Garcia Granero E, Habr Gama A, Hahnloser D, Harris G, Hasegawa H, Holm T, Horgan P, Hyman N, Irwin T, Joh YG, Jongen J, Kaiser A, Kang SB, Kariv Y, Kennedy R, Kessler H, Khan M, Kim SH, Krokowicz P, Kwok S, Lacy A, Larson D, Law WL, Lee E, Lippert H, Ludwig K, Lynch AC, MacRae H, Madbouly K, Maeda K, Marderstein E, Marino M, Marks J, Maurer C, McLeod R, Monson J, Mortensen N, Neary P, Newstead G, OBrien D, Orangio G, Orkin B, Page M, Påhlman L, Panis Y, Panton N, Pennickx F, Phang T, Pinedo Mancilla G, Post S, Rafferty J, Rajput A, Reis Neto dos JA, Rivadeneira D, Roselli J, Rosen H, Rossi G, Rouanet P, Rullier E, Schiedeck T, Schiessel R, Schlachta C, Schwenk W, Seow Choen F, Sim R, Sing WK, Stamos M, Sternberg J, Tuckson W, Vaccaro C, Vargas D, Vignali A, Vonen B, Weiss E, Wexner S, Whiteford M, Wibe A, Williams N, Woods R, Yamamoto T, Young Fadok T., UGOLINI, GIAMPAOLO, Augestad KM, Lindsetmo RO, Stulberg J, Reynolds H, Senagore A, Champagne B, Heriot AG, Leblanc F, Delaney CP, Ambrosetti P, Andujar J, Baixuli J, Balen E, Baxter N, Beck D, Bemelman W, Bergamaschi R, Billingham R, Birch D, Bonardi R, Bonardi M, Bonjer J, Braga M, Buch H, Buechler M, Burnstein M, Campbell K, Caushaj P, Celebrezze J, Chang G, Cheong D, Cohen J, Colak T, Delaney C, Dhoore A, Douglas P, Dozois E, Efron J, Ellis N, Enker W, Fanelli RD, Fazio V, Fleshman J, Franklin M, Fry R, Garcia-Aguilar J, Garcia-Granero E, Habr-Gama A, Hahnloser D, Harris G, Hasegawa H, Holm T, Horgan P, Hyman N, Irwin T, Joh YG, Jongen J, Kaiser A, Kang SB, Kariv Y, Kennedy R, Kessler H, Khan M, Kim SH, Krokowicz P, Kwok S, Lacy A, Larson D, Law WL, Lee E, Lippert H, Ludwig K, Lynch AC, MacRae H, Madbouly K, Maeda K, Marderstein E, Marino M, Marks J, Maurer C, McLeod R, Monson J, Mortensen N, Neary P, Newstead G, OBrien D, Orangio G, Orkin B, Page M, Påhlman L, Panis Y, Panton N, Pennickx F, Phang T, Pinedo Mancilla G, Post S, Rafferty J, Rajput A, Reis Neto dos JA, Rivadeneira D, Roselli J, Rosen H, Rossi G, Rouanet P, Rullier E, Schiedeck T, Schiessel R, Schlachta C, Schwenk W, Seow-Choen F, Sim R, Sing WK, Stamos M, Sternberg J, Tuckson W, Ugolini G, Vaccaro C, Vargas D, Vignali A, Vonen B, Weiss E, Wexner S, Whiteford M, Wibe A, Williams N, Woods R, Yamamoto T, Young-Fadok T., Augestad, K, Lindsetmo, R, Stulberg, J, Reynolds, H, Senagore, A, Champagne, B, Heriot, A, Leblanc, F, Delaney, C, Ambrosetti, P, Andujar, J, Baixuli, J, Balen, E, Baxter, N, Beck, D, Bemelman, W, Bergamaschi, R, Billingham, R, Birch, D, Bonardi, R, Bonardi, M, Bonjer, J, Braga, M, Buch, H, Buechler, M, Burnstein, M, Campbell, K, Caushaj, P, Celebrezze, J, Chang, G, Cheong, D, Cohen, J, Colak, T, Dhoore, A, Douglas, P, Dozois, E, Efron, J, Ellis, N, Enker, W, Fanelli, R, Fazio, V, Fleshman, J, Franklin, M, Fry, R, Garcia-Aguilar, J, Garcia-Granero, E, Habr-Gama, A, Hahnloser, D, Harris, G, Hasegawa, H, Holm, T, Horgan, P, Hyman, N, Irwin, T, Joh, Y, Jongen, J, Kaiser, A, Kang, S, Kariv, Y, Kennedy, R, Kessler, H, Khan, M, Kim, S, Krokowicz, P, Kwok, S, Lacy, A, Larson, D, Law, W, Lee, E, Lippert, H, Ludwig, K, Lynch, A, Macrae, H, Madbouly, K, Maeda, K, Marderstein, E, Marino, M, Marks, J, Maurer, C, Mcleod, R, Monson, J, Mortensen, N, Neary, P, Newstead, G, Obrien, D, Orangio, G, Orkin, B, Page, M, Pahlman, L, Panis, Y, Panton, N, Pennickx, F, Phang, T, Pinedo Mancilla, G, Post, S, Rafferty, J, Rajput, A, Reis Neto dos, J, Rivadeneira, D, Roselli, J, Rosen, H, Rossi, G, Rouanet, P, Rullier, E, Schiedeck, T, Schiessel, R, Schlachta, C, Schwenk, W, Seow-Choen, F, Sim, R, Sing, W, Stamos, M, Sternberg, J, Tuckson, W, Ugolini, G, Vaccaro, C, Vargas, D, Vignali, A, Vonen, B, Weiss, E, Wexner, S, Whiteford, M, Wibe, A, Williams, N, Woods, R, Yamamoto, T, and Young-Fadok, T
- Subjects
medicine.medical_specialty ,Internationality ,Colorectal cancer ,health care facilities, manpower, and services ,medicine.medical_treatment ,education ,Preoperative care ,Article ,RECTAL CANCER ,COLORECTAL SURGERY ,Preoperative Care ,MANAGEMENT ,Medicine ,Humans ,Stage (cooking) ,health care economics and organizations ,Neoadjuvant therapy ,Neoplasm Staging ,Patient Care Team ,Rectal Neoplasm ,medicine.diagnostic_test ,business.industry ,Rectal Neoplasms ,General surgery ,Cancer ,Rectal examination ,Vascular surgery ,medicine.disease ,humanities ,Neoadjuvant Therapy ,Surgery ,Treatment Outcome ,Health Care Survey ,Health Care Surveys ,Practice Guidelines as Topic ,MULTIDISCIPLINARY TEAMS ,Rectal Neoplasms - pathology - surgery - therapy ,business ,Human ,Abdominal surgery - Abstract
Law, WL is one of the members of the International Rectal Cancer Study Group, BACKGROUND: Little is known regarding variations in preoperative treatment and practice for rectal cancer (RC) on an international level, yet practice variation may result in differences in recurrence and survival rates. METHODS: One hundred seventy-three international colorectal centers were invited to participate in a survey of preoperative management of rectal cancer. RESULTS: One hundred twenty-three (71%) responded, with a majority of respondents from North America, Europe, and Asia. Ninety-three percent have more than 5 years' experience with rectal cancer surgery. Fifty-five percent use CT scan, 35% MRI, 29% ERUS, 12% digital rectal examination and 1% PET scan in all RC cases. Seventy-four percent consider threatened circumferential margin (CRM) an indication for neoadjuvant treatment. Ninety-two percent prefer 5-FU-based long-course neoadjuvant chemoradiation therapy (CRT). A significant difference in practice exists between the US and non-US surgeons: poor histological differentiation as an indication for CRT (25% vs. 7.0%, p = 0.008), CRT for stage II and III rectal cancer (92% vs. 43%, p = 0.0001), MRI for all RC patients (20% vs. 42%, p = 0.03), and ERUS for all RC patients (43% vs. 21%, p = 0.01). Multidisciplinary team meetings significantly influence decisions for MRI (RR = 3.62), neoadjuvant treatment (threatened CRM, RR = 5.67, stage II + III RR = 2.98), quality of pathology report (RR = 4.85), and sphincter-saving surgery (RR = 3.81). CONCLUSIONS: There was little consensus on staging, neoadjuvant treatment, and preoperative management of rectal cancer. Regular multidisciplinary team meetings influence decisions about neoadjuvant treatment and staging methods., published_or_final_version
- Published
- 2010
13. International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams
- Author
-
Augestad, K, Lindsetmo, R, Stulberg, J, Reynolds, H, Senagore, A, Champagne, B, Heriot, A, Leblanc, F, Delaney, C, Ambrosetti, P, Andujar, J, Baixuli, J, Balen, E, Baxter, N, Beck, D, Bemelman, W, Bergamaschi, R, Billingham, R, Birch, D, Bonardi, R, Bonardi, M, Bonjer, J, Braga, M, Buch, H, Buechler, M, Burnstein, M, Campbell, K, Caushaj, P, Celebrezze, J, Chang, G, Cheong, D, Cohen, J, Colak, T, Dhoore, A, Douglas, P, Dozois, E, Efron, J, Ellis, N, Enker, W, Fanelli, R, Fazio, V, Fleshman, J, Franklin, M, Fry, R, Garcia-Aguilar, J, Garcia-Granero, E, Habr-Gama, A, Hahnloser, D, Harris, G, Hasegawa, H, Holm, T, Horgan, P, Hyman, N, Irwin, T, Joh, Y, Jongen, J, Kaiser, A, Kang, S, Kariv, Y, Kennedy, R, Kessler, H, Khan, M, Kim, S, Krokowicz, P, Kwok, S, Lacy, A, Larson, D, Law, W, Lee, E, Lippert, H, Ludwig, K, Lynch, A, Macrae, H, Madbouly, K, Maeda, K, Marderstein, E, Marino, M, Marks, J, Maurer, C, Mcleod, R, Monson, J, Mortensen, N, Neary, P, Newstead, G, Obrien, D, Orangio, G, Orkin, B, Page, M, Pahlman, L, Panis, Y, Panton, N, Pennickx, F, Phang, T, Pinedo Mancilla, G, Post, S, Rafferty, J, Rajput, A, Reis Neto dos, J, Rivadeneira, D, Roselli, J, Rosen, H, Rossi, G, Rouanet, P, Rullier, E, Schiedeck, T, Schiessel, R, Schlachta, C, Schwenk, W, Seow-Choen, F, Sim, R, Sing, W, Stamos, M, Sternberg, J, Tuckson, W, Ugolini, G, Vaccaro, C, Vargas, D, Vignali, A, Vonen, B, Weiss, E, Wexner, S, Whiteford, M, Wibe, A, Williams, N, Woods, R, Yamamoto, T, Young-Fadok, T, Augestad K. M., Lindsetmo R. -O., Stulberg J., Reynolds H., Senagore A., Champagne B., Heriot A. G., Leblanc F., Delaney C. P., Ambrosetti P., Andujar J., Baixuli J., Balen E., Baxter N., Beck D., Bemelman W., Bergamaschi R., Billingham R., Birch D., Bonardi R., Bonardi M., Bonjer J., Braga M., Buch H., Buechler M., Burnstein M., Campbell K., Caushaj P., Celebrezze J., Chang G., Cheong D., Cohen J., Colak T., Dhoore A., Douglas P., Dozois E., Efron J., Ellis N., Enker W., Fanelli R. D., Fazio V., Fleshman J., Franklin M., Fry R., Garcia-Aguilar J., Garcia-Granero E., Habr-Gama A., Hahnloser D., Harris G., Hasegawa H., Holm T., Horgan P., Hyman N., Irwin T., Joh Y. G., Jongen J., Kaiser A., Kang S. B., Kariv Y., Kennedy R., Kessler H., Khan M., Kim S. H., Krokowicz P., Kwok S., Lacy A., Larson D., Law W. L., Lee E., Lippert H., Ludwig K., Lynch A. C., MacRae H., Madbouly K., Maeda K., Marderstein E., Marino M., Marks J., Maurer C., McLeod R., Monson J., Mortensen N., Neary P., Newstead G., OBrien D., Orangio G., Orkin B., Page M., Pahlman L., Panis Y., Panton N., Pennickx F., Phang T., Pinedo Mancilla G., Post S., Rafferty J., Rajput A., Reis Neto dos J. A., Rivadeneira D., Roselli J., Rosen H., Rossi G., Rouanet P., Rullier E., Schiedeck T., Schiessel R., Schlachta C., Schwenk W., Seow-Choen F., Sim R., Sing W. K., Stamos M., Sternberg J., Tuckson W., Ugolini G., Vaccaro C., Vargas D., Vignali A., Vonen B., Weiss E., Wexner S., Whiteford M., Wibe A., Williams N., Woods R., Yamamoto T., Young-Fadok T., Augestad, K, Lindsetmo, R, Stulberg, J, Reynolds, H, Senagore, A, Champagne, B, Heriot, A, Leblanc, F, Delaney, C, Ambrosetti, P, Andujar, J, Baixuli, J, Balen, E, Baxter, N, Beck, D, Bemelman, W, Bergamaschi, R, Billingham, R, Birch, D, Bonardi, R, Bonardi, M, Bonjer, J, Braga, M, Buch, H, Buechler, M, Burnstein, M, Campbell, K, Caushaj, P, Celebrezze, J, Chang, G, Cheong, D, Cohen, J, Colak, T, Dhoore, A, Douglas, P, Dozois, E, Efron, J, Ellis, N, Enker, W, Fanelli, R, Fazio, V, Fleshman, J, Franklin, M, Fry, R, Garcia-Aguilar, J, Garcia-Granero, E, Habr-Gama, A, Hahnloser, D, Harris, G, Hasegawa, H, Holm, T, Horgan, P, Hyman, N, Irwin, T, Joh, Y, Jongen, J, Kaiser, A, Kang, S, Kariv, Y, Kennedy, R, Kessler, H, Khan, M, Kim, S, Krokowicz, P, Kwok, S, Lacy, A, Larson, D, Law, W, Lee, E, Lippert, H, Ludwig, K, Lynch, A, Macrae, H, Madbouly, K, Maeda, K, Marderstein, E, Marino, M, Marks, J, Maurer, C, Mcleod, R, Monson, J, Mortensen, N, Neary, P, Newstead, G, Obrien, D, Orangio, G, Orkin, B, Page, M, Pahlman, L, Panis, Y, Panton, N, Pennickx, F, Phang, T, Pinedo Mancilla, G, Post, S, Rafferty, J, Rajput, A, Reis Neto dos, J, Rivadeneira, D, Roselli, J, Rosen, H, Rossi, G, Rouanet, P, Rullier, E, Schiedeck, T, Schiessel, R, Schlachta, C, Schwenk, W, Seow-Choen, F, Sim, R, Sing, W, Stamos, M, Sternberg, J, Tuckson, W, Ugolini, G, Vaccaro, C, Vargas, D, Vignali, A, Vonen, B, Weiss, E, Wexner, S, Whiteford, M, Wibe, A, Williams, N, Woods, R, Yamamoto, T, Young-Fadok, T, Augestad K. M., Lindsetmo R. -O., Stulberg J., Reynolds H., Senagore A., Champagne B., Heriot A. G., Leblanc F., Delaney C. P., Ambrosetti P., Andujar J., Baixuli J., Balen E., Baxter N., Beck D., Bemelman W., Bergamaschi R., Billingham R., Birch D., Bonardi R., Bonardi M., Bonjer J., Braga M., Buch H., Buechler M., Burnstein M., Campbell K., Caushaj P., Celebrezze J., Chang G., Cheong D., Cohen J., Colak T., Dhoore A., Douglas P., Dozois E., Efron J., Ellis N., Enker W., Fanelli R. D., Fazio V., Fleshman J., Franklin M., Fry R., Garcia-Aguilar J., Garcia-Granero E., Habr-Gama A., Hahnloser D., Harris G., Hasegawa H., Holm T., Horgan P., Hyman N., Irwin T., Joh Y. G., Jongen J., Kaiser A., Kang S. B., Kariv Y., Kennedy R., Kessler H., Khan M., Kim S. H., Krokowicz P., Kwok S., Lacy A., Larson D., Law W. L., Lee E., Lippert H., Ludwig K., Lynch A. C., MacRae H., Madbouly K., Maeda K., Marderstein E., Marino M., Marks J., Maurer C., McLeod R., Monson J., Mortensen N., Neary P., Newstead G., OBrien D., Orangio G., Orkin B., Page M., Pahlman L., Panis Y., Panton N., Pennickx F., Phang T., Pinedo Mancilla G., Post S., Rafferty J., Rajput A., Reis Neto dos J. A., Rivadeneira D., Roselli J., Rosen H., Rossi G., Rouanet P., Rullier E., Schiedeck T., Schiessel R., Schlachta C., Schwenk W., Seow-Choen F., Sim R., Sing W. K., Stamos M., Sternberg J., Tuckson W., Ugolini G., Vaccaro C., Vargas D., Vignali A., Vonen B., Weiss E., Wexner S., Whiteford M., Wibe A., Williams N., Woods R., Yamamoto T., and Young-Fadok T.
- Abstract
Background Little is known regarding variations in preoperative treatment and practice for rectal cancer (RC) on an international level, yet practice variation may result in differences in recurrence and survival rates. Methods One hundred seventy-three international colorectal centers were invited to participate in a survey of preoperative management of rectal cancer. Results One hundred twenty-three (71%) responded, with a majority of respondents from North America, Europe, and Asia. Ninety-three percent have more than 5 years' experience with rectal cancer surgery. Fifty-five percent use CT scan, 35% MRI, 29% ERUS, 12% digital rectal examination and 1% PET scan in all RC cases. Seventyfour percent consider threatened circumferential margin (CRM) an indication for neoadjuvant treatment. Ninety-two percent prefer 5-FU-based long-course neoadjuvant chemoradiation therapy (CRT). A significant difference in practice exists between the US and non-US surgeons: poor histological differentiation as an indication for CRT (25% vs. 7.0%, p = 0.008), CRT for stage II and III rectal cancer (92% vs. 43%, p = 0.0001), MRI for all RC patients (20% vs. 42%, p = 0.03), and ERUS for all RC patients (43% vs. 21%, p = 0.01). Multidisciplinary team meetings significantly influence decisions for MRI (RR = 3.62), neoadjuvant treatment (threatened CRM, RR = 5.67, stage II III RR = 2.98), quality of pathology report (RR = 4.85), and sphincter-saving surgery (RR = 3.81). Conclusions There was little consensus on staging, neoadjuvant treatment, and preoperative management of rectal cancer. Regular multidisciplinary team meetings influence decisions about neoadjuvant treatment and staging methods.
- Published
- 2010
14. An RPG II to CP-M Compiler that Works
- Author
-
Roselli, J. and Jensen, P.
- Subjects
Compiler/decompiler ,Report Generation Software ,Microcomputer ,RPG II ,CP/M ,RPG II Compiler Software West - Published
- 1983
15. Telomerase reactivation is associated with hepatobiliary and pancreatic cancers
- Author
-
Francesco Tovoli, Jenny Roselli, Marco Le Grazie, Andrea Galli, Simone Polvani, Mirko Tarocchi, Vito Sansone, Sansone V., Le Grazie M., Roselli J., Polvani S., Galli A., Tovoli F., and Tarocchi M.
- Subjects
Telomerase ,Carcinoma, Hepatocellular ,Hepatobiliary and pancreatic disease ,Adenocarcinoma ,Digestive System Neoplasms ,Cholangiocarcinoma ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Biomarkers, Tumor ,Diagnostic biomarker ,Animals ,Humans ,Telomerase reverse transcriptase ,Cancer ,Hepatology ,business.industry ,Liver Neoplasms ,Gastroenterology ,Telomere Homeostasis ,Telomere ,medicine.disease ,Prognosis ,Enzyme Activation ,Pancreatic Neoplasms ,Bile Duct Neoplasms ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Cancer research ,030211 gastroenterology & hepatology ,business - Abstract
Background Human telomerase reverse transcriptase (hTERT) and its components play a significant role in cancer progression, but recent data demonstrated that telomeres and telomerase alterations could be found in other diseases; increasing evidence suggests a key role of this enzyme in the fields of hepatobiliary and pancreatic diseases. Data sources We performed a PubMed search with the following keywords: telomerase, hepatocellular carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma by December 2019. We reviewed the relevant publications that analyzed the correlation between telomerase activity and hepatobiliary and pancreatic diseases. Results Telomerase reactivation plays a significant role in the development and progression of hepatobiliary and pancreatic tumors and could be used as a diagnostic biomarker for hepatobiliary and pancreatic cancers, as a predictor for prognosis and a promising therapeutic target. Conclusions Our review summarized the evidence about the critical role of hTERT in cancerous and precancerous lesions of the alteration and its activity in hepatobiliary and pancreatic diseases.
- Published
- 2019
16. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves.
- Author
-
Bezzio C, Vernero M, Costa S, Armuzzi A, Fiorino G, Ardizzone S, Roselli J, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Alimenti E, Balestrieri P, Ricci C, Cappello M, Felice C, Coppini F, Alvisi P, Di Luna I, Gerardi V, Variola A, Mazzuoli S, Lenti MV, and Saibeni S
- Subjects
- Humans, Male, Longitudinal Studies, Pandemics, SARS-CoV-2, COVID-19 epidemiology, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases epidemiology
- Abstract
Background: In Italy, the incidence of SARS-CoV-2 infection peaked in April and November 2020, defining two pandemic waves of coronavirus disease 2019 (COVID-19). This study compared the characteristics and outcomes of patients with inflammatory bowel disease (IBD) and SARS-CoV-2 infections between pandemic waves., Methods: Observational longitudinal study of IBD patients with SARS-CoV-2 infection. Patients with established diagnoses of IBD and of SARS-CoV-2 infection were consecutively enrolled in two periods: (i) first wave, from 1 March 2020 to 31 May 2020; and (ii) second wave, from 15 September to 15 December 2020., Results: We enrolled 937 IBD patients (219 in the first wave, 718 in the second wave). Patients of the first wave were older (mean ± SD: 46.3 ± 16.2 vs. 44.1 ± 15.4 years, p = 0.06), more likely to have ulcerative colitis (58.0% vs. 44.4%, p < 0.001) and comorbidities (48.9% vs. 38.9%; p < 0.01), and more frequently residing in Northern Italy (73.1% vs. 46.0%, p < 0.001) than patients of the second wave. There were no significant differences between pandemic waves in sex (male: 54.3% vs. 53.3%, p = 0.82) or frequency of active IBD (44.3% vs. 39.0%, p = 0.18). The rates of negative outcomes were significantly higher in the first than second wave: pneumonia (27.8% vs. 11.7%, p < 0.001), hospital admission (27.4% vs. 9.7%, p < 0.001), ventilatory support (11.9% vs. 5.4%, p < 0.003) and death (5.5% vs. 1.8%, p < 0.007)., Conclusion: Between the first and second SARS-CoV-2 pandemic waves, demographic, clinical and geographical features of IBD patients were different as were the symptoms and outcomes of infection. These differences are likely due to the different epidemiological situations and diagnostic possibilities between the two waves., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
17. Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML.
- Author
-
Strachan DC, Gu CJ, Kita R, Anderson EK, Richardson MA, Yam G, Pimm G, Roselli J, Schweickert A, Terrell M, Rashid R, Gonzalez AK, Oviedo HH, Alozie MC, Ilangovan T, Marcogliese AN, Tada H, Santaguida MT, and Stevens AM
- Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease that accounts for ~20% of all childhood leukemias, and more than 40% of children with AML relapse within three years of diagnosis. Although recent efforts have focused on developing a precise medicine-based approach towards treating AML in adults, there remains a critical gap in therapies designed specifically for children. Here, we present ex vivo drug sensitivity profiles for children with de novo AML using an automated flow cytometry platform. Fresh diagnostic blood or bone marrow aspirate samples were screened for sensitivity in response to 78 dose conditions by measuring the reduction in leukemic blasts relative to the control. In pediatric patients treated with conventional chemotherapy, comprising cytarabine, daunorubicin and etoposide (ADE), ex vivo drug sensitivity results correlated with minimal residual disease (r = 0.63) and one year relapse-free survival (r = 0.70; AUROC = 0.94). In the de novo ADE analysis cohort of 13 patients, AML cells showed greater sensitivity to bortezomib/panobinostat compared with ADE, and comparable sensitivity between venetoclax/azacitidine and ADE ex vivo. Two patients showed a differential response between ADE and bortezomib/panobinostat, thus supporting the incorporation of ex vivo drug sensitivity testing in clinical trials to further evaluate the predictive utility of this platform in children with AML.
- Published
- 2022
- Full Text
- View/download PDF
18. Pregnancy outcomes in inflammatory bowel disease: Data from a large cohort survey.
- Author
-
Innocenti T, Roselli J, Taylor A, Dragoni G, Lynch EN, Campani C, Gottin M, Bagnoli S, Macrì G, Rogai F, Milani S, Galli A, and Milla M
- Subjects
- Infant, Infant, Newborn, Humans, Female, Pregnancy, Pregnancy Outcome, Cesarean Section adverse effects, Surveys and Questionnaires, Premature Birth epidemiology, Premature Birth etiology, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases epidemiology
- Abstract
Objectives: Inflammatory bowel disease (IBD) can affect young and reproductively active patients. Our aim was to analyze pregnancy outcomes in a large cohort of women with IBD., Methods: All women with at least one pregnancy were given a questionnaire regarding the outcome of their pregnancy. They were divided into IBD pregnancies and controls depending on whether pregnancy occurred within or over 10 years prior to the diagnosis of IBD., Results: Three hundred questionnaires were analyzed for a total of 478 pregnancies that led to live-born babies. Age at conception was older in IBD women than in the controls. Active smoking was more frequent in the control group. The risk of intrauterine growth restriction (IUGR) was higher in IBD pregnancies (odds ratio [OR] 3.028, 95% confidence interval [CI] 1.245-7.370, P = 0.013). The week of gestation at delivery was lower in the IBD population. And the risk of cesarean section was higher in IBD pregnancies (OR 1.963, 95% CI 1.274-3.028, P = 0.002). Among women with IBD pregnancy, the risk of preterm birth was higher in patients with active disease at the time of conception (OR 4.088, 95% CI 1.112-15.025, P = 0.030), but lower in patients who continued regular therapy during pregnancy. Similarly, the risk of urgent cesarean section was reduced in the case of disease remission, while the risk of a planned cesarean delivery was higher in patients with perianal disease (OR 11.314, 95% CI 3.550-36.058, P < 0.01)., Conclusions: Our study shows a higher risk of IUGR, cesarean section, and poor blood pressure control in IBD pregnancies. We emphasize the importance of achieving disease remission before considering pregnancy., (© 2022 The Authors. Journal of Digestive Diseases published by Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
19. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
- Author
-
Innocenti T, Roselli J, Lynch EN, Apolito P, Parisio L, Bagnoli S, Macrì G, Rogai F, Tarocchi M, Milani S, Galli A, Milla M, and Dragoni G
- Subjects
- Antibodies, Monoclonal, Humanized, Biological Factors therapeutic use, Gastrointestinal Agents adverse effects, Humans, Retrospective Studies, Tumor Necrosis Factor Inhibitors, Ustekinumab adverse effects, Colitis, Ulcerative chemically induced, Colitis, Ulcerative drug therapy, Colitis, Ulcerative epidemiology, Crohn Disease chemically induced, Crohn Disease drug therapy, Crohn Disease epidemiology, Infections, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases epidemiology
- Abstract
Background and Aims: Vedolizumab is a gut-selective anti-integrin (α4β7) antibody for the treatment of inflammatory bowel disease with a well-known optimal safety profile. We aimed to compare its risk of infections with that of anti-TNF drugs and ustekinumab in patients with both ulcerative colitis and Crohn's disease., Methods: All Crohn's disease and ulcerative colitis patients undergoing biological treatment at our centre between 2013 and 2019 were retrospectively included. All infectious complications were registered, considering both inpatient and outpatient events. A comparison of the exposure-adjusted infection rates of vedolizumab, anti-TNF drugs and ustekinumab was carried out, with a specific focus on the rate of gut infections. All infection rates were expressed in events per patient-years (PYs)., Results: The overall exposure-adjusted infection rate was 11.5/100 PYs. The most common infections were respiratory tract infections, cutaneous infections, HSV infections/reactivations and gut infections. The rate of serious infections was 1.3/100 PYs. The infection rate of vedolizumab was 17.5/100 PYs, with Crohn's disease patients having a lower infection risk compared with ulcerative colitis patients (P = 0.035). Gut infections were observed in 3.0% of the whole patient population (1.5/100 PYs) and were more common in the vedolizumab group (P = 0.0001)., Conclusions: Our study confirms the good safety profile of vedolizumab. Among patients treated with vedolizumab, those with ulcerative colitis have a higher risk of developing infectious complications. Patients treated with vedolizumab have a higher risk of gut infections compared with patients treated with anti-TNF drugs or ustekinumab. Presumably, this is due to the gut-selective mechanism of action of vedolizumab., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
20. Non-small-bowel lesions identification by capsule endoscopy: A single centre retrospective study.
- Author
-
Innocenti T, Dragoni G, Roselli J, Macrì G, Mello T, Milani S, and Galli A
- Subjects
- Colonoscopy, Endoscopy, Gastrointestinal, Gastrointestinal Hemorrhage diagnosis, Gastrointestinal Hemorrhage etiology, Gastroscopy, Humans, Retrospective Studies, Capsule Endoscopy
- Abstract
Background: Capsule endoscopy has been considered the first-line approach for the investigation of obscure gastro-intestinal bleeding since its approval in 2001. Our study aims to evaluate the diagnostic yield of capsule endoscopy in the investigation of this condition. We also analyse the incidence of non-small-bowel lesions missed after conventional endoscopy and later detected by capsule endoscopy in patients with suspected obscure bleeding., Methods: A total of 290 patients with negative conventional endoscopy referred to our centre to undergo a capsule endoscopy examination for the investigation of obscure gastro-intestinal bleeding. We considered as non-small-bowel lesions those outside the tract between the second duodenal portion and the ileocecal valve. We also looked for actively bleeding lesions at the time of the exam., Results: Intestinal preparation was good, adequate or poor in 74.1%, 8.4%, and 17.5% of the tests, respectively. Caecum was reached in 92.4%. Capsule retention occurred in 0.7%. Mean small bowel transit time was 5hours and 13minutes. Diagnostic yield was 73.8%. An actively bleeding lesion was noticed in 39.3% of positive tests. Capsule endoscopy revealed clinically significant non-small-bowel lesions missed at gastroscopy or colonoscopy in 30.3% of patients, 43.2% of which were bleeding., Conclusions: Capsule endoscopy has high diagnostic yield and safety in the investigation of obscure gastro-intestinal bleedings. Given the high percentage of non-small-bowel lesions detected, it may be appropriate to consider an endoscopic second look before performing a capsule endoscopy study., (Copyright © 2020 Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
21. Telomerase reactivation is associated with hepatobiliary and pancreatic cancers.
- Author
-
Sansone V, Le Grazie M, Roselli J, Polvani S, Galli A, Tovoli F, and Tarocchi M
- Subjects
- Adenocarcinoma enzymology, Adenocarcinoma genetics, Animals, Bile Duct Neoplasms enzymology, Bile Duct Neoplasms genetics, Biomarkers, Tumor genetics, Carcinoma, Hepatocellular enzymology, Carcinoma, Hepatocellular genetics, Cholangiocarcinoma enzymology, Cholangiocarcinoma genetics, Digestive System Neoplasms genetics, Enzyme Activation, Humans, Liver Neoplasms enzymology, Liver Neoplasms genetics, Pancreatic Neoplasms enzymology, Pancreatic Neoplasms genetics, Prognosis, Telomerase genetics, Telomere metabolism, Biomarkers, Tumor metabolism, Digestive System Neoplasms enzymology, Telomerase metabolism, Telomere enzymology, Telomere Homeostasis
- Abstract
Background: Human telomerase reverse transcriptase (hTERT) and its components play a significant role in cancer progression, but recent data demonstrated that telomeres and telomerase alterations could be found in other diseases; increasing evidence suggests a key role of this enzyme in the fields of hepatobiliary and pancreatic diseases., Data Sources: We performed a PubMed search with the following keywords: telomerase, hepatocellular carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma by December 2019. We reviewed the relevant publications that analyzed the correlation between telomerase activity and hepatobiliary and pancreatic diseases., Results: Telomerase reactivation plays a significant role in the development and progression of hepatobiliary and pancreatic tumors and could be used as a diagnostic biomarker for hepatobiliary and pancreatic cancers, as a predictor for prognosis and a promising therapeutic target., Conclusions: Our review summarized the evidence about the critical role of hTERT in cancerous and precancerous lesions of the alteration and its activity in hepatobiliary and pancreatic diseases., (Copyright © 2020 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
22. Stevens-Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn's Disease.
- Author
-
Roselli J, Innocenti T, Lynch EN, Parisio L, Apolito P, Mello T, Macrì G, Milla M, Biagini MR, Tarocchi M, Milani S, and Galli A
- Abstract
Stevens-Johnson syndrome (SJS) is a severe mucocutaneous adverse drug reaction with a relatively high mortality rate. SJS is described during herpes simplex virus type 1 (HSV1) infection and, rarely, even during adalimumab therapy. We report the case of a patient with Crohn's disease who developed SJS during an HSV1 infection and a contemporaneous anti-TNF α therapy with adalimumab. Remission was achieved with suspension of adalimumab and high doses of intravenous steroids and antivirals. Patients with HSV1 infection and on adalimumab therapy have a combined risk of SJS and should be monitored closely., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2020 Jenny Roselli et al.)
- Published
- 2020
- Full Text
- View/download PDF
23. Increased Risk of Liver Cirrhosis during Azathioprine Therapy for Crohn's Disease.
- Author
-
Roselli J, Innocenti T, Lynch EN, Parisio L, Macrì G, Milla M, Mello T, Galli A, Milani S, and Tarocchi M
- Abstract
Azathioprine is a cornerstone of the therapy of Crohn's disease. Unfortunately, infections and malignancies are relatively common adverse effects related to this drug; however, cirrhosis is exceptionally reported as a side effect. We report the case of a 49-year-old male patient with ileocolonic steno-penetrating Crohn's disease who developed hepatic cirrhosis while treated with azathioprine. After taking azathioprine for 3 years with regular follow-up, he developed pancytopenia, and liver cirrhosis was diagnosed with ultrasound, abdomen computed tomography scan, transient elastography, and liver biopsy. As all other causes of liver damage were excluded, azathioprine was believed to be the cause of liver injury and therefore was interrupted., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2020 Jenny Roselli et al.)
- Published
- 2020
- Full Text
- View/download PDF
24. Subcutaneous Direct-to-Implant Breast Reconstruction: Surgical, Functional, and Aesthetic Results after Long-Term Follow-Up.
- Author
-
Bernini M, Calabrese C, Cecconi L, Santi C, Gjondedaj U, Roselli J, Nori J, Fausto A, Orzalesi L, and Casella D
- Abstract
Unlabelled: Direct-to-implant breast reconstruction can be achieved more easily by means of soft-tissue replacement devices such as dermal matrices and synthetic meshes. The feasibility of a subcutaneous approach has been recently investigated by some studies with different devices functioning as implant support. Aim of this study is to analyze the long-term results, both objective and subjective, of a previous nonrandomized trial comparing prepectoral (subcutaneous) and retropectoral breast reconstructions., Methods: Patients enrolled in a nonrandomized prospective trial, comparing the standard retropectoral reconstruction and the prepectoral subcutaneous approach, using a titanium-coated mesh in both techniques, were followed up and evaluated for long-term results. Cases were compared in terms of the causes and rate of reinterventions, of the postoperative BREAST-Q questionnaire results, and of an objective surgical evaluation., Results: The subcutaneous group had a rate of implant failure and removal of 5.1% when compared with 0% in the retropectoral group. Aesthetic outcome was significantly better for the subcutaneous group both at a subjective and at an objective evaluation. Capsular contracture rate was 0% in the subcutaneous group., Conclusions: A higher rate of implant failure and removal, although not significant, always because of skin flaps and wound problems, should be taken into account for a careful patients selection. The subcutaneous breast reconstruction shows good long-term results. A coherent subjective and objective cosmetic advantage of this approach emerges. Moreover, no capsular contracture is evident, albeit in a relatively limited number of cases.
- Published
- 2016
- Full Text
- View/download PDF
25. TiLoop® Bra mesh used for immediate breast reconstruction: comparison of retropectoral and subcutaneous implant placement in a prospective single-institution series.
- Author
-
Casella D, Bernini M, Bencini L, Roselli J, Lacaria MT, Martellucci J, Banfi R, Calabrese C, and Orzalesi L
- Abstract
Background: Immediate implant reconstruction after a conservative mastectomy is an attractive option made easier by prosthetic devices. Titanized polypropylene meshes are used as a hammock to cover the lower lateral implant pole. We conducted a prospective nonrandomized single-institution study of reconstructions using titanium-coated meshes either in a standard muscular mesh pocket or in a complete subcutaneous approach. The complete subcutaneous approach means to wrap an implant with titanized mesh in order to position the implant subcutaneously and spare muscles., Methods: Between November 2011 and January 2014, we performed immediate implant breast reconstructions after conservative mastectomies using TiLoop® Bra, either with the standard retropectoral or with a prepectoral approach. Selection criteria included only women with normal Body Mass Index (BMI), no large and very ptotic breasts, no history of smoking, no diabetes, and no previous radiotherapy. We analyzed short-term outcomes of such procedures and compared the outcomes to evaluate implant losses and surgical complications., Results: A total of 73 mastectomies were performed. Group 1 comprised 29 women, 5 bilateral procedures, 34 reconstructions, using the standard muscular mesh pocket. Group 2 comprised 34 women, 5 bilateral procedures, 39 reconstructions with the prepectoral subcutaneous technique. Baseline and oncologic characteristics were homogeneous between the two groups. After a median follow-up period of 13 and 12 months, respectively, no implant losses were recorded in group 1, and one implant loss was recorded in group 2. We registered three surgical complications in group 1 and two surgical complications in group 2., Conclusions: Titanium-coated polypropylene meshes, as a tool for immediate definitive implant breast reconstruction, resulted as safe and effective in a short-term analysis, both for a retropectoral and a totally subcutaneous implant placement. Long-term results are forthcoming. A strict selection is mandatory to achieve optimal results. Level of Evidence: Level II, therapeutic study.
- Published
- 2014
- Full Text
- View/download PDF
26. [Clinical considerations on hepatitis in infants and children].
- Author
-
MORANO BRANDI JF, ROSELLI J, BLANCO C, de CAINO VE, SABBIONE RM, DELLEDONNE RJ, and ACTIS DATO A
- Subjects
- Child, Humans, Infant, Hepatitis, Hepatitis A
- Published
- 1951
27. [Evolution of diffuse acute glomerulonephritis in children].
- Author
-
ROSELLI J, BLANCO C, and ALMONACID JB
- Subjects
- Child, Infant, Biological Evolution, Glomerulonephritis
- Published
- 1953
28. [Congenital syphilis in 11-month-old infant].
- Author
-
ROSELLI J
- Subjects
- Humans, Infant, Syphilis, Syphilis, Congenital
- Published
- 1950
29. [THE STARTING PERIOD OF TUBERCULOUS MENINGITIS. ANALYSIS OF 131 CLINICAL OBSERVATIONS].
- Author
-
ROSELLI J, ROJAS P, INCHAURREGUI G, and ARRUA R
- Subjects
- Adolescent, Child, Humans, Infant, Prognosis, BCG Vaccine, Cerebrospinal Fluid, Clinical Laboratory Techniques, Diagnosis, Differential, Epidemiology, Laboratories, Mycobacterium bovis, Tuberculosis, Tuberculosis, Meningeal, Vaccination
- Published
- 1964
30. [Pleuropulmonary suppurations in infants].
- Author
-
MAZZA JA, ROSELLI J, DELLEDONNE R, GOROSTIAGUE S, RIVA JC, and PETRUCELLI M
- Subjects
- Child, Humans, Infant, Lung Abscess, Suppuration
- Published
- 1961
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.